{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:25:52Z","timestamp":1788474352303,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1093\/jac\/dkq127","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T21:29:27Z","timestamp":1272662967000},"page":"1441-1447","source":"Crossref","is-referenced-by-count":45,"title":["Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae"],"prefix":"10.1093","volume":"65","author":[{"given":"Wolfgang","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Pillar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine K.","family":"Hesje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,4,30]]},"reference":[{"key":"key\n\t\t\t\t20170425163327_DKQ127C1","first-page":"5","article-title":"Mechanisms of action and resistance to quinolone antimicrobial agents","volume-title":"Quinolone Antimicrobial Agents","author":"Wolfson","year":"1989"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C2","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.00418-09","article-title":"Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria","volume":"53","author":"Haas","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C3","volume-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A","author":"Clinical and Laboratory Standards Institute","year":"1999"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C4","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C5","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18.","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C6","doi-asserted-by":"publisher","DOI":"10.1201\/9781420014495","volume-title":"Antimicrobial Susceptibility Testing Protocols","author":"Schwalbe","year":"2007"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-8579(96)00320-2","article-title":"Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens","volume":"7","author":"Ferrara","year":"1996","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C8","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1128\/AAC.47.4.1410-1415.2003","article-title":"Activity of and resistance to moxifloxacin in Staphylococcus aureus","volume":"47","author":"Ince","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C10","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.01586-05","article-title":"Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance","volume":"50","author":"Ba","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.44.3.633-639.2000","article-title":"Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0732-8893(03)00037-3","article-title":"Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs","volume":"46","author":"Horii","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C13","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/AAC.46.6.1651-1657.2002","article-title":"In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV","volume":"46","author":"Jones","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00646-06","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration\u2013time curve\/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin","volume":"51","author":"LaPlante","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C15","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/AAC.42.12.3293","article-title":"Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis","volume":"42","author":"Li","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C16","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1128\/AAC.48.9.3570-3572.2004","article-title":"Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV","volume":"48","author":"Li","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1128\/JCM.42.3.1185-1191.2004","article-title":"Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations","volume":"42","author":"Perez-Vazquez","year":"2004","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjo.2007.129858","article-title":"Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones","volume":"92","author":"Yamada","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkn528","article-title":"Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli","volume":"63","author":"Cambau","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/jop.2008.0116","article-title":"Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans","volume":"25","author":"Proksch","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jop.2006.0137","article-title":"Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use","volume":"23","author":"Ward","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clinthera.2009.03.010","article-title":"Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study","volume":"31","author":"Karpecki","year":"2009","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C23","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ophtha.2009.05.014","article-title":"Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis","volume":"116","author":"McDonald","year":"2009","journal-title":"Ophthalmology"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1185\/03007990902837919","article-title":"Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis","volume":"25","author":"Tepedino","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijantimicag.2004.03.011","article-title":"In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model","volume":"24","author":"Allen","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170425163327_DKQ127C27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijantimicag.2004.02.021","article-title":"Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus","volume":"24","author":"Metzler","year":"2004","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/65\/7\/1441\/13762028\/dkq127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:56:09Z","timestamp":1559066169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkq127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,30]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,4,30]]},"published-print":{"date-parts":[[2010,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkq127","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4,30]]}}}